Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
Sodium zirconium cyclosilicate (SZC) has been demonstrated for its serum potassium-lowering efficacy and safety in hyperkalemia hemodialysis patients. However, the effects of SZC during the perioperative period remained unknown. This experiment aimed to determine whether using SZC would impact the serum potassium levels in patients with maintenance hemodialysis after parathyroidectomy (PTX).
Epistemonikos ID: 995e37964b5413eb642aced935e9fa1099dd181c
First added on: May 13, 2024